secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001787306-25-000122
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis
--------------------------------------------------------------------------------

- Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.
- Net loss narrowed to $15.9M ($0.13/sh) from $52.3M ($0.42/sh) YoY; cash $191.1M as of June 30.
- ZORYVE foam 0.3% approved in May 2025 for scalp/body psoriasis; sales commenced in June.
- PDUFA date Oct 13, 2025 for ZORYVE cream 0.05% in children 2–5 with atopic dermatitis.
- IND submitted for ARQ-234 (CD200R agonist); halted ARQ-255 (alopecia areata) program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/0001787306-25-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/arqt-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer